nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CBR1—Doxorubicin—urinary bladder cancer	0.253	0.457	CbGbCtD
Haloperidol—ABCB1—Mitomycin—urinary bladder cancer	0.0737	0.133	CbGbCtD
Haloperidol—CYP3A4—Thiotepa—urinary bladder cancer	0.0335	0.0605	CbGbCtD
Haloperidol—CYP3A5—Etoposide—urinary bladder cancer	0.0233	0.0421	CbGbCtD
Haloperidol—ABCB1—Gemcitabine—urinary bladder cancer	0.0212	0.0384	CbGbCtD
Haloperidol—CYP1A2—Fluorouracil—urinary bladder cancer	0.0208	0.0375	CbGbCtD
Haloperidol—CYP2C9—Fluorouracil—urinary bladder cancer	0.0187	0.0338	CbGbCtD
Haloperidol—CYP1A2—Etoposide—urinary bladder cancer	0.0173	0.0313	CbGbCtD
Haloperidol—CYP2C9—Cisplatin—urinary bladder cancer	0.0159	0.0287	CbGbCtD
Haloperidol—ABCB1—Cisplatin—urinary bladder cancer	0.0154	0.0279	CbGbCtD
Haloperidol—ABCB1—Etoposide—urinary bladder cancer	0.0151	0.0274	CbGbCtD
Haloperidol—ABCB1—Doxorubicin—urinary bladder cancer	0.0103	0.0187	CbGbCtD
Haloperidol—ABCB1—Methotrexate—urinary bladder cancer	0.01	0.0181	CbGbCtD
Haloperidol—CYP2D6—Doxorubicin—urinary bladder cancer	0.00973	0.0176	CbGbCtD
Haloperidol—CYP3A4—Etoposide—urinary bladder cancer	0.00908	0.0164	CbGbCtD
Haloperidol—CYP3A4—Doxorubicin—urinary bladder cancer	0.00619	0.0112	CbGbCtD
Haloperidol—CYP2C19—urine—urinary bladder cancer	0.00427	0.0445	CbGeAlD
Haloperidol—EBP—female reproductive system—urinary bladder cancer	0.00372	0.0387	CbGeAlD
Haloperidol—CYP1A2—urine—urinary bladder cancer	0.00349	0.0363	CbGeAlD
Haloperidol—CYP2C9—urine—urinary bladder cancer	0.00331	0.0345	CbGeAlD
Haloperidol—CBR1—prostate gland—urinary bladder cancer	0.0031	0.0323	CbGeAlD
Haloperidol—UGT1A9—renal system—urinary bladder cancer	0.00281	0.0293	CbGeAlD
Haloperidol—HTR2A—urine—urinary bladder cancer	0.00273	0.0284	CbGeAlD
Haloperidol—CBR1—seminal vesicle—urinary bladder cancer	0.00263	0.0274	CbGeAlD
Haloperidol—H1F0—prostate gland—urinary bladder cancer	0.00254	0.0265	CbGeAlD
Haloperidol—CYP3A4—urine—urinary bladder cancer	0.00252	0.0263	CbGeAlD
Haloperidol—CYP2D6—urine—urinary bladder cancer	0.00248	0.0259	CbGeAlD
Haloperidol—H1F0—seminal vesicle—urinary bladder cancer	0.00215	0.0224	CbGeAlD
Haloperidol—CBR1—renal system—urinary bladder cancer	0.00212	0.022	CbGeAlD
Haloperidol—CBR1—urethra—urinary bladder cancer	0.00208	0.0217	CbGeAlD
Haloperidol—CBR1—Azacitidine—Gemcitabine—urinary bladder cancer	0.00197	0.595	CbGdCrCtD
Haloperidol—SIGMAR1—prostate gland—urinary bladder cancer	0.00184	0.0191	CbGeAlD
Haloperidol—H1F0—smooth muscle tissue—urinary bladder cancer	0.0018	0.0188	CbGeAlD
Haloperidol—H1F0—renal system—urinary bladder cancer	0.00173	0.0181	CbGeAlD
Haloperidol—H1F0—urethra—urinary bladder cancer	0.0017	0.0177	CbGeAlD
Haloperidol—CBR1—female reproductive system—urinary bladder cancer	0.00169	0.0177	CbGeAlD
Haloperidol—SIGMAR1—seminal vesicle—urinary bladder cancer	0.00155	0.0162	CbGeAlD
Haloperidol—CBR1—vagina—urinary bladder cancer	0.00153	0.016	CbGeAlD
Haloperidol—KCNH2—prostate gland—urinary bladder cancer	0.00146	0.0152	CbGeAlD
Haloperidol—H1F0—female reproductive system—urinary bladder cancer	0.00139	0.0145	CbGeAlD
Haloperidol—EBP—Azacitidine—Gemcitabine—urinary bladder cancer	0.00134	0.405	CbGdCrCtD
Haloperidol—SIGMAR1—smooth muscle tissue—urinary bladder cancer	0.0013	0.0136	CbGeAlD
Haloperidol—HTR2B—smooth muscle tissue—urinary bladder cancer	0.0013	0.0135	CbGeAlD
Haloperidol—H1F0—vagina—urinary bladder cancer	0.00126	0.0131	CbGeAlD
Haloperidol—KCNH2—seminal vesicle—urinary bladder cancer	0.00124	0.0129	CbGeAlD
Haloperidol—SIGMAR1—urethra—urinary bladder cancer	0.00123	0.0128	CbGeAlD
Haloperidol—CYP3A5—prostate gland—urinary bladder cancer	0.00121	0.0126	CbGeAlD
Haloperidol—HRH1—prostate gland—urinary bladder cancer	0.00117	0.0122	CbGeAlD
Haloperidol—HTR1B—female reproductive system—urinary bladder cancer	0.00111	0.0116	CbGeAlD
Haloperidol—HTR1D—female reproductive system—urinary bladder cancer	0.00108	0.0112	CbGeAlD
Haloperidol—HTR2B—female reproductive system—urinary bladder cancer	0.001	0.0104	CbGeAlD
Haloperidol—KCNH2—renal system—urinary bladder cancer	0.000996	0.0104	CbGeAlD
Haloperidol—CBR1—lymph node—urinary bladder cancer	0.000991	0.0103	CbGeAlD
Haloperidol—KCNH2—urethra—urinary bladder cancer	0.000979	0.0102	CbGeAlD
Haloperidol—CYP1A1—epithelium—urinary bladder cancer	0.000907	0.00945	CbGeAlD
Haloperidol—SIGMAR1—vagina—urinary bladder cancer	0.000907	0.00945	CbGeAlD
Haloperidol—HTR2B—vagina—urinary bladder cancer	0.000905	0.00943	CbGeAlD
Haloperidol—HRH1—epithelium—urinary bladder cancer	0.000861	0.00897	CbGeAlD
Haloperidol—CYP1A2—renal system—urinary bladder cancer	0.000853	0.00889	CbGeAlD
Haloperidol—CYP1A1—renal system—urinary bladder cancer	0.000841	0.00877	CbGeAlD
Haloperidol—HRH1—smooth muscle tissue—urinary bladder cancer	0.00083	0.00864	CbGeAlD
Haloperidol—CYP1A1—urethra—urinary bladder cancer	0.000827	0.00861	CbGeAlD
Haloperidol—CYP3A5—renal system—urinary bladder cancer	0.000823	0.00857	CbGeAlD
Haloperidol—H1F0—lymph node—urinary bladder cancer	0.000812	0.00846	CbGeAlD
Haloperidol—KCNH2—female reproductive system—urinary bladder cancer	0.000798	0.00831	CbGeAlD
Haloperidol—HRH1—urethra—urinary bladder cancer	0.000784	0.00817	CbGeAlD
Haloperidol—CYP2C19—vagina—urinary bladder cancer	0.000756	0.00788	CbGeAlD
Haloperidol—KCNH2—vagina—urinary bladder cancer	0.000722	0.00752	CbGeAlD
Haloperidol—HTR2A—epithelium—urinary bladder cancer	0.000719	0.00749	CbGeAlD
Haloperidol—HTR2A—smooth muscle tissue—urinary bladder cancer	0.000693	0.00722	CbGeAlD
Haloperidol—CYP1A1—female reproductive system—urinary bladder cancer	0.000674	0.00702	CbGeAlD
Haloperidol—HTR2A—renal system—urinary bladder cancer	0.000667	0.00695	CbGeAlD
Haloperidol—CYP2C9—female reproductive system—urinary bladder cancer	0.000648	0.00676	CbGeAlD
Haloperidol—ABCB1—prostate gland—urinary bladder cancer	0.000641	0.00668	CbGeAlD
Haloperidol—HRH1—female reproductive system—urinary bladder cancer	0.00064	0.00666	CbGeAlD
Haloperidol—CYP3A4—renal system—urinary bladder cancer	0.000617	0.00643	CbGeAlD
Haloperidol—CYP1A1—vagina—urinary bladder cancer	0.000609	0.00635	CbGeAlD
Haloperidol—CYP2D6—renal system—urinary bladder cancer	0.000608	0.00633	CbGeAlD
Haloperidol—CYP3A5—vagina—urinary bladder cancer	0.000596	0.00621	CbGeAlD
Haloperidol—SIGMAR1—lymph node—urinary bladder cancer	0.000586	0.00611	CbGeAlD
Haloperidol—HTR2B—lymph node—urinary bladder cancer	0.000585	0.0061	CbGeAlD
Haloperidol—HRH1—vagina—urinary bladder cancer	0.000578	0.00603	CbGeAlD
Haloperidol—ABCB1—seminal vesicle—urinary bladder cancer	0.000542	0.00565	CbGeAlD
Haloperidol—HTR2A—female reproductive system—urinary bladder cancer	0.000534	0.00557	CbGeAlD
Haloperidol—CYP3A4—female reproductive system—urinary bladder cancer	0.000494	0.00515	CbGeAlD
Haloperidol—CYP2D6—female reproductive system—urinary bladder cancer	0.000487	0.00507	CbGeAlD
Haloperidol—HTR2A—vagina—urinary bladder cancer	0.000483	0.00503	CbGeAlD
Haloperidol—ABCB1—epithelium—urinary bladder cancer	0.000471	0.00491	CbGeAlD
Haloperidol—KCNH2—lymph node—urinary bladder cancer	0.000467	0.00486	CbGeAlD
Haloperidol—ABCB1—renal system—urinary bladder cancer	0.000437	0.00455	CbGeAlD
Haloperidol—ABCB1—urethra—urinary bladder cancer	0.000429	0.00447	CbGeAlD
Haloperidol—CYP1A1—lymph node—urinary bladder cancer	0.000394	0.00411	CbGeAlD
Haloperidol—HRH1—lymph node—urinary bladder cancer	0.000374	0.0039	CbGeAlD
Haloperidol—ABCB1—female reproductive system—urinary bladder cancer	0.00035	0.00365	CbGeAlD
Haloperidol—ABCB1—vagina—urinary bladder cancer	0.000317	0.0033	CbGeAlD
Haloperidol—Constipation—Gemcitabine—urinary bladder cancer	0.000271	0.00145	CcSEcCtD
Haloperidol—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000271	0.00145	CcSEcCtD
Haloperidol—Pancytopenia—Methotrexate—urinary bladder cancer	0.000271	0.00145	CcSEcCtD
Haloperidol—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000271	0.00145	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000269	0.00144	CcSEcCtD
Haloperidol—Dysphagia—Epirubicin—urinary bladder cancer	0.000267	0.00143	CcSEcCtD
Haloperidol—Neutropenia—Methotrexate—urinary bladder cancer	0.000267	0.00143	CcSEcCtD
Haloperidol—Pruritus—Thiotepa—urinary bladder cancer	0.000267	0.00143	CcSEcCtD
Haloperidol—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000265	0.00142	CcSEcCtD
Haloperidol—Tachycardia—Etoposide—urinary bladder cancer	0.000264	0.00142	CcSEcCtD
Haloperidol—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000264	0.00141	CcSEcCtD
Haloperidol—Dyspnoea—Cisplatin—urinary bladder cancer	0.000263	0.00141	CcSEcCtD
Haloperidol—Skin disorder—Etoposide—urinary bladder cancer	0.000263	0.00141	CcSEcCtD
Haloperidol—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000263	0.00141	CcSEcCtD
Haloperidol—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000262	0.0014	CcSEcCtD
Haloperidol—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000261	0.0014	CcSEcCtD
Haloperidol—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000261	0.0014	CcSEcCtD
Haloperidol—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00026	0.00139	CcSEcCtD
Haloperidol—Breast disorder—Doxorubicin—urinary bladder cancer	0.000258	0.00138	CcSEcCtD
Haloperidol—Anorexia—Etoposide—urinary bladder cancer	0.000258	0.00138	CcSEcCtD
Haloperidol—Diarrhoea—Thiotepa—urinary bladder cancer	0.000258	0.00138	CcSEcCtD
Haloperidol—Decreased appetite—Cisplatin—urinary bladder cancer	0.000257	0.00138	CcSEcCtD
Haloperidol—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000257	0.00138	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000255	0.00137	CcSEcCtD
Haloperidol—Drowsiness—Methotrexate—urinary bladder cancer	0.000254	0.00136	CcSEcCtD
Haloperidol—Depression—Methotrexate—urinary bladder cancer	0.000254	0.00136	CcSEcCtD
Haloperidol—Pancytopenia—Epirubicin—urinary bladder cancer	0.000253	0.00136	CcSEcCtD
Haloperidol—Hypotension—Etoposide—urinary bladder cancer	0.000253	0.00136	CcSEcCtD
Haloperidol—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000251	0.00134	CcSEcCtD
Haloperidol—Neutropenia—Epirubicin—urinary bladder cancer	0.00025	0.00134	CcSEcCtD
Haloperidol—Dizziness—Thiotepa—urinary bladder cancer	0.000249	0.00134	CcSEcCtD
Haloperidol—Urticaria—Fluorouracil—urinary bladder cancer	0.000248	0.00133	CcSEcCtD
Haloperidol—Dysphagia—Doxorubicin—urinary bladder cancer	0.000247	0.00132	CcSEcCtD
Haloperidol—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000246	0.00132	CcSEcCtD
Haloperidol—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000244	0.00131	CcSEcCtD
Haloperidol—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000244	0.0013	CcSEcCtD
Haloperidol—Weight increased—Epirubicin—urinary bladder cancer	0.000243	0.0013	CcSEcCtD
Haloperidol—Weight decreased—Epirubicin—urinary bladder cancer	0.000241	0.00129	CcSEcCtD
Haloperidol—Dyspnoea—Etoposide—urinary bladder cancer	0.000241	0.00129	CcSEcCtD
Haloperidol—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000241	0.00129	CcSEcCtD
Haloperidol—Somnolence—Etoposide—urinary bladder cancer	0.000241	0.00129	CcSEcCtD
Haloperidol—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00024	0.00129	CcSEcCtD
Haloperidol—Vomiting—Thiotepa—urinary bladder cancer	0.00024	0.00128	CcSEcCtD
Haloperidol—Drowsiness—Epirubicin—urinary bladder cancer	0.000238	0.00127	CcSEcCtD
Haloperidol—Rash—Thiotepa—urinary bladder cancer	0.000238	0.00127	CcSEcCtD
Haloperidol—Dermatitis—Thiotepa—urinary bladder cancer	0.000237	0.00127	CcSEcCtD
Haloperidol—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000237	0.00127	CcSEcCtD
Haloperidol—Headache—Thiotepa—urinary bladder cancer	0.000236	0.00127	CcSEcCtD
Haloperidol—Decreased appetite—Etoposide—urinary bladder cancer	0.000235	0.00126	CcSEcCtD
Haloperidol—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000235	0.00126	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000234	0.00125	CcSEcCtD
Haloperidol—Body temperature increased—Cisplatin—urinary bladder cancer	0.000234	0.00125	CcSEcCtD
Haloperidol—Jaundice—Epirubicin—urinary bladder cancer	0.000232	0.00124	CcSEcCtD
Haloperidol—Constipation—Etoposide—urinary bladder cancer	0.000232	0.00124	CcSEcCtD
Haloperidol—Neutropenia—Doxorubicin—urinary bladder cancer	0.000231	0.00124	CcSEcCtD
Haloperidol—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00023	0.00123	CcSEcCtD
Haloperidol—Hepatitis—Methotrexate—urinary bladder cancer	0.000228	0.00122	CcSEcCtD
Haloperidol—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000225	0.00121	CcSEcCtD
Haloperidol—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000225	0.00121	CcSEcCtD
Haloperidol—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000225	0.00121	CcSEcCtD
Haloperidol—Weight increased—Doxorubicin—urinary bladder cancer	0.000225	0.0012	CcSEcCtD
Haloperidol—Pruritus—Gemcitabine—urinary bladder cancer	0.000224	0.0012	CcSEcCtD
Haloperidol—Nausea—Thiotepa—urinary bladder cancer	0.000224	0.0012	CcSEcCtD
Haloperidol—Urethral disorder—Methotrexate—urinary bladder cancer	0.000224	0.0012	CcSEcCtD
Haloperidol—Weight decreased—Doxorubicin—urinary bladder cancer	0.000223	0.0012	CcSEcCtD
Haloperidol—Feeling abnormal—Etoposide—urinary bladder cancer	0.000223	0.0012	CcSEcCtD
Haloperidol—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000223	0.00119	CcSEcCtD
Haloperidol—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000222	0.00119	CcSEcCtD
Haloperidol—Pruritus—Fluorouracil—urinary bladder cancer	0.000221	0.00118	CcSEcCtD
Haloperidol—Drowsiness—Doxorubicin—urinary bladder cancer	0.00022	0.00118	CcSEcCtD
Haloperidol—Visual impairment—Methotrexate—urinary bladder cancer	0.00022	0.00118	CcSEcCtD
Haloperidol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000218	0.00117	CcSEcCtD
Haloperidol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000217	0.00116	CcSEcCtD
Haloperidol—Urticaria—Etoposide—urinary bladder cancer	0.000215	0.00115	CcSEcCtD
Haloperidol—Jaundice—Doxorubicin—urinary bladder cancer	0.000215	0.00115	CcSEcCtD
Haloperidol—Body temperature increased—Etoposide—urinary bladder cancer	0.000214	0.00115	CcSEcCtD
Haloperidol—Hepatitis—Epirubicin—urinary bladder cancer	0.000214	0.00114	CcSEcCtD
Haloperidol—Eye disorder—Methotrexate—urinary bladder cancer	0.000213	0.00114	CcSEcCtD
Haloperidol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000213	0.00114	CcSEcCtD
Haloperidol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000212	0.00114	CcSEcCtD
Haloperidol—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000211	0.00113	CcSEcCtD
Haloperidol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00021	0.00112	CcSEcCtD
Haloperidol—Urethral disorder—Epirubicin—urinary bladder cancer	0.000209	0.00112	CcSEcCtD
Haloperidol—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000208	0.00112	CcSEcCtD
Haloperidol—Angiopathy—Methotrexate—urinary bladder cancer	0.000207	0.00111	CcSEcCtD
Haloperidol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000206	0.0011	CcSEcCtD
Haloperidol—Dizziness—Fluorouracil—urinary bladder cancer	0.000206	0.0011	CcSEcCtD
Haloperidol—Visual impairment—Epirubicin—urinary bladder cancer	0.000206	0.0011	CcSEcCtD
Haloperidol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000206	0.0011	CcSEcCtD
Haloperidol—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000205	0.0011	CcSEcCtD
Haloperidol—ABCB1—lymph node—urinary bladder cancer	0.000205	0.00213	CbGeAlD
Haloperidol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000202	0.00108	CcSEcCtD
Haloperidol—Alopecia—Methotrexate—urinary bladder cancer	0.000202	0.00108	CcSEcCtD
Haloperidol—Vomiting—Gemcitabine—urinary bladder cancer	0.000202	0.00108	CcSEcCtD
Haloperidol—Mental disorder—Methotrexate—urinary bladder cancer	0.0002	0.00107	CcSEcCtD
Haloperidol—Rash—Gemcitabine—urinary bladder cancer	0.0002	0.00107	CcSEcCtD
Haloperidol—Dermatitis—Gemcitabine—urinary bladder cancer	0.0002	0.00107	CcSEcCtD
Haloperidol—Eye disorder—Epirubicin—urinary bladder cancer	0.0002	0.00107	CcSEcCtD
Haloperidol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000199	0.00107	CcSEcCtD
Haloperidol—Malnutrition—Methotrexate—urinary bladder cancer	0.000199	0.00106	CcSEcCtD
Haloperidol—Headache—Gemcitabine—urinary bladder cancer	0.000199	0.00106	CcSEcCtD
Haloperidol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000198	0.00106	CcSEcCtD
Haloperidol—Vomiting—Fluorouracil—urinary bladder cancer	0.000198	0.00106	CcSEcCtD
Haloperidol—Hepatitis—Doxorubicin—urinary bladder cancer	0.000198	0.00106	CcSEcCtD
Haloperidol—Rash—Fluorouracil—urinary bladder cancer	0.000197	0.00105	CcSEcCtD
Haloperidol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000196	0.00105	CcSEcCtD
Haloperidol—Headache—Fluorouracil—urinary bladder cancer	0.000195	0.00105	CcSEcCtD
Haloperidol—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000195	0.00105	CcSEcCtD
Haloperidol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000194	0.00104	CcSEcCtD
Haloperidol—Angiopathy—Epirubicin—urinary bladder cancer	0.000194	0.00104	CcSEcCtD
Haloperidol—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000194	0.00104	CcSEcCtD
Haloperidol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000193	0.00103	CcSEcCtD
Haloperidol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000193	0.00103	CcSEcCtD
Haloperidol—Pruritus—Etoposide—urinary bladder cancer	0.000192	0.00103	CcSEcCtD
Haloperidol—Visual impairment—Doxorubicin—urinary bladder cancer	0.00019	0.00102	CcSEcCtD
Haloperidol—Alopecia—Epirubicin—urinary bladder cancer	0.000189	0.00101	CcSEcCtD
Haloperidol—Nausea—Gemcitabine—urinary bladder cancer	0.000188	0.00101	CcSEcCtD
Haloperidol—Vomiting—Cisplatin—urinary bladder cancer	0.000188	0.00101	CcSEcCtD
Haloperidol—Vision blurred—Methotrexate—urinary bladder cancer	0.000187	0.001	CcSEcCtD
Haloperidol—Mental disorder—Epirubicin—urinary bladder cancer	0.000187	0.001	CcSEcCtD
Haloperidol—Rash—Cisplatin—urinary bladder cancer	0.000186	0.000998	CcSEcCtD
Haloperidol—Dermatitis—Cisplatin—urinary bladder cancer	0.000186	0.000997	CcSEcCtD
Haloperidol—Malnutrition—Epirubicin—urinary bladder cancer	0.000186	0.000996	CcSEcCtD
Haloperidol—Diarrhoea—Etoposide—urinary bladder cancer	0.000185	0.000993	CcSEcCtD
Haloperidol—Nausea—Fluorouracil—urinary bladder cancer	0.000185	0.000992	CcSEcCtD
Haloperidol—Eye disorder—Doxorubicin—urinary bladder cancer	0.000185	0.00099	CcSEcCtD
Haloperidol—Anaemia—Methotrexate—urinary bladder cancer	0.000184	0.000984	CcSEcCtD
Haloperidol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000183	0.000983	CcSEcCtD
Haloperidol—Angiopathy—Doxorubicin—urinary bladder cancer	0.000179	0.000961	CcSEcCtD
Haloperidol—Dizziness—Etoposide—urinary bladder cancer	0.000179	0.000959	CcSEcCtD
Haloperidol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000179	0.000958	CcSEcCtD
Haloperidol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000179	0.000957	CcSEcCtD
Haloperidol—Vertigo—Methotrexate—urinary bladder cancer	0.000179	0.000957	CcSEcCtD
Haloperidol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000178	0.000954	CcSEcCtD
Haloperidol—Leukopenia—Methotrexate—urinary bladder cancer	0.000178	0.000953	CcSEcCtD
Haloperidol—Nausea—Cisplatin—urinary bladder cancer	0.000176	0.000941	CcSEcCtD
Haloperidol—Vision blurred—Epirubicin—urinary bladder cancer	0.000175	0.000939	CcSEcCtD
Haloperidol—Alopecia—Doxorubicin—urinary bladder cancer	0.000175	0.000936	CcSEcCtD
Haloperidol—Mental disorder—Doxorubicin—urinary bladder cancer	0.000173	0.000928	CcSEcCtD
Haloperidol—Convulsion—Methotrexate—urinary bladder cancer	0.000172	0.000922	CcSEcCtD
Haloperidol—Vomiting—Etoposide—urinary bladder cancer	0.000172	0.000922	CcSEcCtD
Haloperidol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000172	0.000922	CcSEcCtD
Haloperidol—Anaemia—Epirubicin—urinary bladder cancer	0.000172	0.000921	CcSEcCtD
Haloperidol—Agitation—Epirubicin—urinary bladder cancer	0.000171	0.000916	CcSEcCtD
Haloperidol—Rash—Etoposide—urinary bladder cancer	0.000171	0.000915	CcSEcCtD
Haloperidol—Dermatitis—Etoposide—urinary bladder cancer	0.000171	0.000914	CcSEcCtD
Haloperidol—Headache—Etoposide—urinary bladder cancer	0.00017	0.000909	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000168	0.0009	CcSEcCtD
Haloperidol—Vertigo—Epirubicin—urinary bladder cancer	0.000167	0.000895	CcSEcCtD
Haloperidol—Leukopenia—Epirubicin—urinary bladder cancer	0.000166	0.000892	CcSEcCtD
Haloperidol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000165	0.000886	CcSEcCtD
Haloperidol—Confusional state—Methotrexate—urinary bladder cancer	0.000164	0.000876	CcSEcCtD
Haloperidol—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000162	0.000869	CcSEcCtD
Haloperidol—Vision blurred—Doxorubicin—urinary bladder cancer	0.000162	0.000869	CcSEcCtD
Haloperidol—Convulsion—Epirubicin—urinary bladder cancer	0.000161	0.000863	CcSEcCtD
Haloperidol—Nausea—Etoposide—urinary bladder cancer	0.000161	0.000862	CcSEcCtD
Haloperidol—Hypertension—Epirubicin—urinary bladder cancer	0.000161	0.00086	CcSEcCtD
Haloperidol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000159	0.000852	CcSEcCtD
Haloperidol—Anaemia—Doxorubicin—urinary bladder cancer	0.000159	0.000852	CcSEcCtD
Haloperidol—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000159	0.000851	CcSEcCtD
Haloperidol—Agitation—Doxorubicin—urinary bladder cancer	0.000158	0.000847	CcSEcCtD
Haloperidol—Anxiety—Epirubicin—urinary bladder cancer	0.000158	0.000845	CcSEcCtD
Haloperidol—Skin disorder—Methotrexate—urinary bladder cancer	0.000158	0.000844	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000157	0.000842	CcSEcCtD
Haloperidol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000157	0.00084	CcSEcCtD
Haloperidol—Dry mouth—Epirubicin—urinary bladder cancer	0.000155	0.00083	CcSEcCtD
Haloperidol—Vertigo—Doxorubicin—urinary bladder cancer	0.000155	0.000828	CcSEcCtD
Haloperidol—Anorexia—Methotrexate—urinary bladder cancer	0.000155	0.000828	CcSEcCtD
Haloperidol—Leukopenia—Doxorubicin—urinary bladder cancer	0.000154	0.000825	CcSEcCtD
Haloperidol—Confusional state—Epirubicin—urinary bladder cancer	0.000153	0.00082	CcSEcCtD
Haloperidol—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000152	0.000813	CcSEcCtD
Haloperidol—Oedema—Epirubicin—urinary bladder cancer	0.000152	0.000813	CcSEcCtD
Haloperidol—Hypotension—Methotrexate—urinary bladder cancer	0.000152	0.000812	CcSEcCtD
Haloperidol—Convulsion—Doxorubicin—urinary bladder cancer	0.000149	0.000799	CcSEcCtD
Haloperidol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000149	0.000797	CcSEcCtD
Haloperidol—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000149	0.000796	CcSEcCtD
Haloperidol—Hypertension—Doxorubicin—urinary bladder cancer	0.000149	0.000796	CcSEcCtD
Haloperidol—Tachycardia—Epirubicin—urinary bladder cancer	0.000148	0.000794	CcSEcCtD
Haloperidol—Skin disorder—Epirubicin—urinary bladder cancer	0.000147	0.00079	CcSEcCtD
Haloperidol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000147	0.000786	CcSEcCtD
Haloperidol—Insomnia—Methotrexate—urinary bladder cancer	0.000147	0.000786	CcSEcCtD
Haloperidol—Anxiety—Doxorubicin—urinary bladder cancer	0.000146	0.000782	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000145	0.000779	CcSEcCtD
Haloperidol—Anorexia—Epirubicin—urinary bladder cancer	0.000145	0.000775	CcSEcCtD
Haloperidol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000145	0.000775	CcSEcCtD
Haloperidol—Somnolence—Methotrexate—urinary bladder cancer	0.000144	0.000772	CcSEcCtD
Haloperidol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000143	0.000768	CcSEcCtD
Haloperidol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000143	0.000765	CcSEcCtD
Haloperidol—Hypotension—Epirubicin—urinary bladder cancer	0.000142	0.00076	CcSEcCtD
Haloperidol—Confusional state—Doxorubicin—urinary bladder cancer	0.000142	0.000759	CcSEcCtD
Haloperidol—Decreased appetite—Methotrexate—urinary bladder cancer	0.000141	0.000755	CcSEcCtD
Haloperidol—Oedema—Doxorubicin—urinary bladder cancer	0.00014	0.000752	CcSEcCtD
Haloperidol—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00014	0.000752	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00014	0.00075	CcSEcCtD
Haloperidol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000138	0.000738	CcSEcCtD
Haloperidol—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000137	0.000737	CcSEcCtD
Haloperidol—Insomnia—Epirubicin—urinary bladder cancer	0.000137	0.000735	CcSEcCtD
Haloperidol—Tachycardia—Doxorubicin—urinary bladder cancer	0.000137	0.000734	CcSEcCtD
Haloperidol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000136	0.000731	CcSEcCtD
Haloperidol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000136	0.000727	CcSEcCtD
Haloperidol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000135	0.000725	CcSEcCtD
Haloperidol—Somnolence—Epirubicin—urinary bladder cancer	0.000135	0.000723	CcSEcCtD
Haloperidol—Anorexia—Doxorubicin—urinary bladder cancer	0.000134	0.000717	CcSEcCtD
Haloperidol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000134	0.000716	CcSEcCtD
Haloperidol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000134	0.000716	CcSEcCtD
Haloperidol—Decreased appetite—Epirubicin—urinary bladder cancer	0.000132	0.000707	CcSEcCtD
Haloperidol—Hypotension—Doxorubicin—urinary bladder cancer	0.000131	0.000703	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000131	0.000702	CcSEcCtD
Haloperidol—Constipation—Epirubicin—urinary bladder cancer	0.00013	0.000695	CcSEcCtD
Haloperidol—Urticaria—Methotrexate—urinary bladder cancer	0.000129	0.00069	CcSEcCtD
Haloperidol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000128	0.000687	CcSEcCtD
Haloperidol—Insomnia—Doxorubicin—urinary bladder cancer	0.000127	0.00068	CcSEcCtD
Haloperidol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000125	0.000671	CcSEcCtD
Haloperidol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000125	0.00067	CcSEcCtD
Haloperidol—Somnolence—Doxorubicin—urinary bladder cancer	0.000125	0.000669	CcSEcCtD
Haloperidol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000124	0.000662	CcSEcCtD
Haloperidol—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000122	0.000654	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000121	0.00065	CcSEcCtD
Haloperidol—Urticaria—Epirubicin—urinary bladder cancer	0.000121	0.000646	CcSEcCtD
Haloperidol—Constipation—Doxorubicin—urinary bladder cancer	0.00012	0.000643	CcSEcCtD
Haloperidol—Body temperature increased—Epirubicin—urinary bladder cancer	0.00012	0.000643	CcSEcCtD
Haloperidol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000119	0.00064	CcSEcCtD
Haloperidol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000116	0.00062	CcSEcCtD
Haloperidol—Pruritus—Methotrexate—urinary bladder cancer	0.000115	0.000615	CcSEcCtD
Haloperidol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000112	0.000599	CcSEcCtD
Haloperidol—Urticaria—Doxorubicin—urinary bladder cancer	0.000112	0.000598	CcSEcCtD
Haloperidol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000111	0.000595	CcSEcCtD
Haloperidol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000111	0.000595	CcSEcCtD
Haloperidol—Pruritus—Epirubicin—urinary bladder cancer	0.000107	0.000575	CcSEcCtD
Haloperidol—Dizziness—Methotrexate—urinary bladder cancer	0.000107	0.000575	CcSEcCtD
Haloperidol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000104	0.000556	CcSEcCtD
Haloperidol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000103	0.000554	CcSEcCtD
Haloperidol—Vomiting—Methotrexate—urinary bladder cancer	0.000103	0.000552	CcSEcCtD
Haloperidol—Rash—Methotrexate—urinary bladder cancer	0.000102	0.000548	CcSEcCtD
Haloperidol—Dermatitis—Methotrexate—urinary bladder cancer	0.000102	0.000547	CcSEcCtD
Haloperidol—Headache—Methotrexate—urinary bladder cancer	0.000102	0.000544	CcSEcCtD
Haloperidol—Dizziness—Epirubicin—urinary bladder cancer	0.0001	0.000538	CcSEcCtD
Haloperidol—Pruritus—Doxorubicin—urinary bladder cancer	9.93e-05	0.000532	CcSEcCtD
Haloperidol—Vomiting—Epirubicin—urinary bladder cancer	9.65e-05	0.000517	CcSEcCtD
Haloperidol—Nausea—Methotrexate—urinary bladder cancer	9.63e-05	0.000516	CcSEcCtD
Haloperidol—Diarrhoea—Doxorubicin—urinary bladder cancer	9.61e-05	0.000515	CcSEcCtD
Haloperidol—Rash—Epirubicin—urinary bladder cancer	9.57e-05	0.000513	CcSEcCtD
Haloperidol—Dermatitis—Epirubicin—urinary bladder cancer	9.56e-05	0.000512	CcSEcCtD
Haloperidol—Headache—Epirubicin—urinary bladder cancer	9.51e-05	0.000509	CcSEcCtD
Haloperidol—Dizziness—Doxorubicin—urinary bladder cancer	9.29e-05	0.000498	CcSEcCtD
Haloperidol—Nausea—Epirubicin—urinary bladder cancer	9.01e-05	0.000483	CcSEcCtD
Haloperidol—Vomiting—Doxorubicin—urinary bladder cancer	8.93e-05	0.000478	CcSEcCtD
Haloperidol—Rash—Doxorubicin—urinary bladder cancer	8.85e-05	0.000474	CcSEcCtD
Haloperidol—Dermatitis—Doxorubicin—urinary bladder cancer	8.85e-05	0.000474	CcSEcCtD
Haloperidol—Headache—Doxorubicin—urinary bladder cancer	8.8e-05	0.000471	CcSEcCtD
Haloperidol—Nausea—Doxorubicin—urinary bladder cancer	8.34e-05	0.000447	CcSEcCtD
Haloperidol—HTR1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.02e-05	6.35e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—RHOA—urinary bladder cancer	1.02e-05	6.32e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.02e-05	6.31e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—ERBB2—urinary bladder cancer	1.01e-05	6.29e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	1.01e-05	6.28e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.01e-05	6.26e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CXCL8—urinary bladder cancer	1.01e-05	6.25e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—HRAS—urinary bladder cancer	1e-05	6.21e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.99e-06	6.2e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL2—urinary bladder cancer	9.99e-06	6.2e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.98e-06	6.19e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	9.96e-06	6.18e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	9.94e-06	6.17e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTEN—urinary bladder cancer	9.93e-06	6.16e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	9.83e-06	6.1e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL2—urinary bladder cancer	9.78e-06	6.07e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CCND1—urinary bladder cancer	9.74e-06	6.04e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	9.67e-06	6e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	9.65e-06	5.99e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NQO1—urinary bladder cancer	9.65e-06	5.99e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL2—urinary bladder cancer	9.62e-06	5.97e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CXCL8—urinary bladder cancer	9.61e-06	5.96e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—TYMS—urinary bladder cancer	9.6e-06	5.96e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	9.58e-06	5.94e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—ERBB2—urinary bladder cancer	9.56e-06	5.93e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.56e-06	5.93e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—HRAS—urinary bladder cancer	9.55e-06	5.93e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CCND1—urinary bladder cancer	9.53e-06	5.92e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	9.5e-06	5.9e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	9.49e-06	5.89e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	9.49e-06	5.89e-05	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—EP300—urinary bladder cancer	9.47e-06	5.88e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	9.45e-06	5.87e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—ERBB2—urinary bladder cancer	9.43e-06	5.85e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.42e-06	5.85e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	9.42e-06	5.84e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	9.4e-06	5.83e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CCND1—urinary bladder cancer	9.38e-06	5.82e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—TYMS—urinary bladder cancer	9.37e-06	5.82e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.36e-06	5.81e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.27e-06	5.75e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.27e-06	5.75e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MMP9—urinary bladder cancer	9.25e-06	5.74e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.24e-06	5.73e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.24e-06	5.73e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	9.22e-06	5.72e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PTEN—urinary bladder cancer	9.2e-06	5.71e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	9.19e-06	5.7e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.11e-06	5.66e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MMP9—urinary bladder cancer	9.11e-06	5.65e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—GPX1—urinary bladder cancer	9.09e-06	5.64e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—CDKN1A—urinary bladder cancer	9.07e-06	5.63e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CXCL8—urinary bladder cancer	9.06e-06	5.63e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PTEN—urinary bladder cancer	9.05e-06	5.62e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—HRAS—urinary bladder cancer	9.01e-06	5.59e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.96e-06	5.56e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	8.96e-06	5.56e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	8.95e-06	5.56e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CXCL8—urinary bladder cancer	8.94e-06	5.55e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	8.93e-06	5.54e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—HRAS—urinary bladder cancer	8.89e-06	5.51e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—GPX1—urinary bladder cancer	8.87e-06	5.51e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—TYMS—urinary bladder cancer	8.83e-06	5.48e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PPARG—urinary bladder cancer	8.8e-06	5.46e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EP300—urinary bladder cancer	8.77e-06	5.45e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—TYMS—urinary bladder cancer	8.76e-06	5.43e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	8.73e-06	5.42e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	8.73e-06	5.42e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	8.71e-06	5.41e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ERCC2—urinary bladder cancer	8.71e-06	5.41e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	8.69e-06	5.4e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	8.66e-06	5.38e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL2—urinary bladder cancer	8.66e-06	5.38e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	8.66e-06	5.37e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	8.66e-06	5.37e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	8.64e-06	5.36e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EP300—urinary bladder cancer	8.63e-06	5.36e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	8.62e-06	5.35e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL2—urinary bladder cancer	8.55e-06	5.3e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SRC—urinary bladder cancer	8.53e-06	5.3e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	8.51e-06	5.28e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	8.48e-06	5.26e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	8.47e-06	5.25e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	8.46e-06	5.25e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	8.45e-06	5.25e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CCND1—urinary bladder cancer	8.44e-06	5.24e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SRC—urinary bladder cancer	8.4e-06	5.21e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	8.39e-06	5.21e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	8.37e-06	5.2e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.36e-06	5.19e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	8.36e-06	5.19e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTEN—urinary bladder cancer	8.35e-06	5.18e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CCND1—urinary bladder cancer	8.33e-06	5.17e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	8.33e-06	5.17e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PPARG—urinary bladder cancer	8.31e-06	5.16e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	8.31e-06	5.16e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.29e-06	5.14e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	8.24e-06	5.12e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.21e-06	5.09e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MMP9—urinary bladder cancer	8.2e-06	5.09e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.19e-06	5.08e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	8.17e-06	5.07e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.17e-06	5.07e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTEN—urinary bladder cancer	8.15e-06	5.06e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8.14e-06	5.05e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MMP9—urinary bladder cancer	8.09e-06	5.02e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—CDKN1A—urinary bladder cancer	8.06e-06	5e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	8.05e-06	5e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTEN—urinary bladder cancer	8.04e-06	4.99e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	8.02e-06	4.97e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	8e-06	4.96e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	7.99e-06	4.96e-05	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—EP300—urinary bladder cancer	7.96e-06	4.94e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	7.87e-06	4.88e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	7.85e-06	4.87e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	7.81e-06	4.85e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	7.8e-06	4.84e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.79e-06	4.83e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EP300—urinary bladder cancer	7.77e-06	4.82e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.72e-06	4.79e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	7.67e-06	4.76e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EP300—urinary bladder cancer	7.67e-06	4.76e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	7.65e-06	4.75e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	7.65e-06	4.75e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	7.65e-06	4.75e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	7.64e-06	4.74e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SRC—urinary bladder cancer	7.56e-06	4.69e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—MYC—urinary bladder cancer	7.52e-06	4.67e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.48e-06	4.64e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	7.48e-06	4.64e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SRC—urinary bladder cancer	7.46e-06	4.63e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.45e-06	4.62e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.4e-06	4.59e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.4e-06	4.59e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	7.36e-06	4.57e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	7.22e-06	4.48e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	7.22e-06	4.48e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	7.18e-06	4.46e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	7.1e-06	4.41e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	7.09e-06	4.4e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—GPX1—urinary bladder cancer	7.08e-06	4.4e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	7.06e-06	4.38e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	7.03e-06	4.36e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.95e-06	4.32e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	6.95e-06	4.31e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	6.92e-06	4.3e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	6.84e-06	4.25e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PPARG—urinary bladder cancer	6.8e-06	4.22e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	6.8e-06	4.22e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—MYC—urinary bladder cancer	6.77e-06	4.2e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	6.73e-06	4.18e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	6.72e-06	4.17e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	6.69e-06	4.15e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—MYC—urinary bladder cancer	6.68e-06	4.15e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	6.68e-06	4.14e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.64e-06	4.12e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	6.64e-06	4.12e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	6.63e-06	4.11e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL2—urinary bladder cancer	6.54e-06	4.06e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	6.54e-06	4.06e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.54e-06	4.06e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	6.54e-06	4.06e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	6.54e-06	4.06e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	6.44e-06	3.99e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL2—urinary bladder cancer	6.42e-06	3.99e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	6.41e-06	3.98e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.38e-06	3.96e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	6.38e-06	3.96e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	6.28e-06	3.9e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	6.27e-06	3.89e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	6.26e-06	3.88e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	6.26e-06	3.88e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.26e-06	3.88e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.21e-06	3.86e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.2e-06	3.85e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	6.19e-06	3.84e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—urinary bladder cancer	6.18e-06	3.83e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	6.18e-06	3.83e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.17e-06	3.83e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	6.15e-06	3.82e-05	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	6.13e-06	3.81e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	6.09e-06	3.78e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	6.08e-06	3.77e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.07e-06	3.77e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.06e-06	3.76e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	6.06e-06	3.76e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	6.04e-06	3.75e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTEN—urinary bladder cancer	6.04e-06	3.75e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	6.01e-06	3.73e-05	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	6.01e-06	3.73e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	5.96e-06	3.7e-05	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	5.91e-06	3.67e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	5.9e-06	3.66e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EP300—urinary bladder cancer	5.87e-06	3.64e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.78e-06	3.58e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	5.77e-06	3.58e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EP300—urinary bladder cancer	5.76e-06	3.58e-05	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—EP300—urinary bladder cancer	5.76e-06	3.57e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.71e-06	3.54e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.71e-06	3.54e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SRC—urinary bladder cancer	5.71e-06	3.54e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTEN—urinary bladder cancer	5.7e-06	3.54e-05	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	5.64e-06	3.5e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	5.62e-06	3.48e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SRC—urinary bladder cancer	5.6e-06	3.48e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—urinary bladder cancer	5.56e-06	3.45e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—urinary bladder cancer	5.49e-06	3.41e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.47e-06	3.39e-05	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—EP300—urinary bladder cancer	5.44e-06	3.38e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.37e-06	3.33e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.35e-06	3.32e-05	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	5.32e-06	3.3e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.3e-06	3.29e-05	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	5.25e-06	3.26e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.22e-06	3.24e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MYC—urinary bladder cancer	5.11e-06	3.17e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.09e-06	3.16e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.05e-06	3.13e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	5.03e-06	3.12e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MYC—urinary bladder cancer	5.02e-06	3.12e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	5e-06	3.1e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.92e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	4.92e-06	3.05e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	4.91e-06	3.05e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.88e-06	3.03e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	4.73e-06	2.93e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.67e-06	2.9e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	4.65e-06	2.89e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	4.64e-06	2.88e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.56e-06	2.83e-05	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.45e-06	2.76e-05	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—EP300—urinary bladder cancer	4.34e-06	2.7e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.29e-06	2.66e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.26e-06	2.64e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—urinary bladder cancer	4.2e-06	2.61e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.17e-06	2.59e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	4.13e-06	2.56e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—urinary bladder cancer	4.12e-06	2.56e-05	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.09e-06	2.54e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.09e-06	2.54e-05	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.06e-06	2.52e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	4.02e-06	2.49e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	3.95e-06	2.45e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	3.94e-06	2.45e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.93e-06	2.44e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.64e-06	2.26e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.47e-06	2.15e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.22e-06	2e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.81e-06	1.74e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.68e-06	1.66e-05	CbGpPWpGaD
